دورية أكاديمية
أعرض في EDS

Decreased Risk of Preeclampsia in Women with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy.

التفاصيل البيبلوغرافية
العنوان: Decreased Risk of Preeclampsia in Women with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy.
المؤلفون: Patel NB; Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA. patel.nisha3@mayo.edu., Vinsard DG; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA., Kattah AG; Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA., Kane SV; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
المصدر: Digestive diseases and sciences [Dig Dis Sci] 2023 Sep; Vol. 68 (9), pp. 3557-3561. Date of Electronic Publication: 2023 Jul 05.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Science + Business Media Country of Publication: United States NLM ID: 7902782 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-2568 (Electronic) Linking ISSN: 01632116 NLM ISO Abbreviation: Dig Dis Sci Subsets: MEDLINE
أسماء مطبوعة: Publication: 2005- : New York, NY : Springer Science + Business Media
Original Publication: New York, Plenum Pub. Corp.
مواضيع طبية MeSH: Pre-Eclampsia*/epidemiology , Inflammatory Bowel Diseases*/complications , Inflammatory Bowel Diseases*/drug therapy, Pregnancy ; Infant, Newborn ; Humans ; Female ; Tumor Necrosis Factor Inhibitors/adverse effects ; Infliximab/adverse effects ; Adalimumab/adverse effects ; Tumor Necrosis Factor-alpha ; Necrosis
مستخلص: Background: Evidence suggests that upregulation of tumor necrosis factor-alpha (TNF-α) plays a role in immune dysregulation in both preeclampsia and inflammatory bowel disease (IBD).
Aims: We aimed to investigate whether anti-TNF therapy during pregnancy decreases the risk of preeclampsia in women with IBD.
Methods: The study population included women with IBD and pregnancies who were followed at a tertiary care center from 2007 to 2021. Cases of preeclampsia were compared with controls with a normotensive pregnancy. Data on patient demographics, disease type and activity, pregnancy complications, and additional risk factors for preeclampsia were collected. The association between anti-TNF therapy and preeclampsia was analyzed using univariate analysis and multivariate logistic regression.
Results: Women with preeclampsia were more likely to have a preterm delivery (44% vs. 12%, p < 0.001). More women without preeclampsia were exposed to anti-TNF therapy during pregnancy than women with preeclampsia (55% vs. 30%, p = 0.029). The majority of women (32/44) on anti-TNF therapy, either adalimumab or infliximab, continued to have some degree of exposure during the third trimester. Though not significant, multivariate analysis showed a trend towards a protective effect of anti-TNF therapy against developing preeclampsia if exposed during the third trimester (OR 0.39; 95% CI 0.14-1.12, p = 0.08).
Conclusions: In this study, anti-TNF therapy exposure was higher in IBD patients who did not develop preeclampsia than in those who did. While not significant, there was a trend towards a protective effect of anti-TNF therapy against preeclampsia if exposed during the third trimester.
(© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
References: Seki H, Matuoka K, Inooku H, Takeda S. TNF-alpha from monocyte of patients with pre-eclampsia-induced apoptosis in human trophoblast cell line. J Obstet Gynaecol Res. 2007;33:408–416. (PMID: 10.1111/j.1447-0756.2007.00551.x17688605)
Sakamoto T, Saito Y, Nakajima T, Matsuda T. Comparison of magnifying chromoendoscopy and narrow-band imaging in estimation of early colorectal cancer invasion depth: a pilot study. Dig Endosc. 2011;23:118–123. (PMID: 10.1111/j.1443-1661.2010.01049.x21429015)
Reinecker H-CSM, Witthoeft T. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol. 2008;94:174–181. (PMID: 10.1111/j.1365-2249.1993.tb05997.x)
Vitoratos N, Economou E, Iavazzo C, Panoulis K, Creatsas G. Maternal serum levels of TNF-alpha and IL-6 long after delivery in preeclamptic and normotensive pregnant women. Mediators Inflamm. 2010;2010:908649. (PMID: 10.1155/2010/908649212535063021880)
Mahadevan U, Cucchiara S, Hyams JS et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011;106:214–223. (PMID: 10.1038/ajg.2010.46421157441)
Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol. 2009;104:228–233. (PMID: 10.1038/ajg.2008.7119098873)
van der Woude CJ, Ardizzone S, Bengtson MB et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9:107–124. (PMID: 10.1093/ecco-jcc/jju00625602023)
Mahadevan U, Wolf DC, Dubinsky M et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286–292. (PMID: 10.1016/j.cgh.2012.11.01123200982)
Mahadevan U, Robinson C, Bernasko N et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology 2019;156:1508–1524. (PMID: 10.1053/j.gastro.2018.12.02230658060)
Nguyen GC, Seow CH, Maxwell C et al. The Toronto Consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology 2016;150:734–757. (PMID: 10.1053/j.gastro.2015.12.00326688268)
Seirafi M, de Vroey B, Amiot A et al. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40:363–373. (PMID: 10.1111/apt.1283324980270)
Meyer A, Drouin J, Weill A. Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010–2018. Aliment Pharmacol Ther. 2021;54:302–311. (PMID: 10.1111/apt.1644834162011)
De Felice KM, Kane S. Safety of anti-TNF agents in pregnancy. J Allergy Clin Immunol. 2021;148:661–667. (PMID: 10.1016/j.jaci.2021.07.00534489011)
Restellini S, Biedermann L, Hruz P et al. Update on the management of inflammatory bowel disease during pregnancy and breastfeeding. Digestion 2020;101:27–42. (PMID: 10.1159/00050288631914444)
Julsgaard M, Hvas CL, Gearry RB et al. Anti-TNF therapy in pregnant women with inflammatory bowel disease: effects of therapeutic strategies on disease behavior and birth outcomes. Inflamm Bowel Dis. 2020;26:93–102. (PMID: 10.1093/ibd/izz11031141607)
Bush MC, Patel S, Lapinski RH, Stone JL. Perinatal outcomes in inflammatory bowel disease. J Matern Fetal Neonatal Med. 2004;15:237–241. (PMID: 10.1080/1476705041000166866215280131)
Stephansson O, Larsson H, Pedersen L et al. Crohn’s disease is a risk factor for preterm birth. Clin Gastroenterol Hepatol. 2010;8:509–515. (PMID: 10.1016/j.cgh.2010.02.01420202483)
LeFevre ML, Force USPST. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161:819–826. (PMID: 10.7326/M14-188425200125)
Betteridge JD, Armbruster SP, Maydonovitch C, Veerappan GR. Inflammatory bowel disease prevalence by age, gender, race, and geographic location in the U.S. military health care population. Inflamm Bowel Dis. 2013;19:1421–1427. (PMID: 10.1097/MIB.0b013e318281334d23518811)
فهرسة مساهمة: Keywords: Anti-TNF; Crohn’s disease; Inflammatory bowel disease; Preeclampsia; Pregnancy; TNF-α; Ulcerative colitis
المشرفين على المادة: 0 (Tumor Necrosis Factor Inhibitors)
B72HH48FLU (Infliximab)
FYS6T7F842 (Adalimumab)
0 (Tumor Necrosis Factor-alpha)
تواريخ الأحداث: Date Created: 20230704 Date Completed: 20230824 Latest Revision: 20230826
رمز التحديث: 20240628
DOI: 10.1007/s10620-023-08016-x
PMID: 37402980
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-2568
DOI:10.1007/s10620-023-08016-x